Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma

Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma

PurposeGlioma is one of the most common tumors of the central nervous system, and many patients suffer from recurrence even after standard comprehensive treatment. However, little is known about the molecular markers that predict the recurrence patterns of glioma. This study aimed to demonstrate the...

Full description

Bibliographic Details
Main Authors:	Shunnan Ge, Yingwu Shi, Gang Zhu, Songlun Li, Yaning Cai, Peigang Ji, Jinghui Liu, Wei Guo, Li Gong, Miao Lou, Fuqiang Feng, Yuan Wang, Yulong Zhai, Yan Qu, Liang Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Oncology
Subjects:	glioma local recurrence paraventricular recurrence molecular markers O6-Methylguanine DNA methyltransferase
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.565045/full

Similar Items

Behavior-Oriented Nomogram for the Stratification of Lower-Grade Gliomas to Improve Individualized Treatment
by: Ruo-Lun Wei, et al.
Published: (2020-12-01)

O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity
by: Valeria Barresi, et al.
Published: (2018-01-01)

Research and application progress of MGMT promoter methylation in gliomas
by: Cui-yun SUN, et al.
Published: (2014-07-01)

Prognostic genetic markers in malignant gliomas
by: Ralf Ketter, et al.
Published: (2010-12-01)

Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
by: Mao-Yu Chen, et al.
Published: (2017-01-01)

Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo
by: Thomas C. Chen, et al.
Published: (2018-09-01)

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis
by: Yu-Hang Zhao, et al.
Published: (2018-03-01)

O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications
by: Jaime A. Oliver, et al.
Published: (2019-09-01)

Glioma SOX2 expression decreased after adjuvant therapy
by: Wei Yu, et al.
Published: (2019-11-01)

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
by: Paul Daniel, et al.
Published: (2019-02-01)

Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas
by: Arsela Prelaj, et al.
Published: (2018-04-01)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
by: Ruichao Chai, et al.
Published: (2021-02-01)

Surgical and therapeutic strategy of recurrent malignant gliomas in intractable location
by: Yun⁃tao LU, et al.
Published: (2012-12-01)

A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG)
by: Maurizio Amichetti, et al.
Published: (2011-10-01)

Enhanced γ-Glutamyltranspeptidase Imaging That Unravels the Glioma Recurrence in Post-radio/Chemotherapy Mixtures for Precise Pathology via Enzyme-Triggered Fluorescent Probe
by: Ben Shi, et al.
Published: (2019-05-01)

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma
by: Wen-Jen Hwu, et al.
Published: (2011-12-01)

Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue
by: Francine B. de Abreu, et al.
Published: (2014-01-01)

Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome
by: Lou L, et al.
Published: (2020-10-01)

Local Delivery of Minocycline and Vorinostat Targets the Tumor Microenvironment to Inhibit the Recurrence of Glioma
by: Zhao G, et al.
Published: (2020-11-01)

Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)

Etoposide Therapy for Recurrent Gliomas
by: J Gordon Millichap
Published: (1997-06-01)

Strategy of awake surgical resection for glioma based on intraoperative functional mapping and monitoring: A case report
by: Yingwu Shi, et al.
Published: (2020-01-01)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
by: Zhang H, et al.
Published: (2017-02-01)

Dual-energy spectral CT quantitative parameters for the differentiation of Glioma recurrence from treatment-related changes: a preliminary study
by: Yanchun Lv, et al.
Published: (2020-01-01)

Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors
by: Chhanda Das, et al.
Published: (2019-10-01)

MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients
by: Dorota Jesionek-Kupnicka, et al.
Published: (2017-07-01)

The prognostic impact of O 6- methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: A clinicopathologic and immunohistochemical study of seven cases at a single institution
by: Jui-Wei Lin, et al.
Published: (2011-01-01)

Pineal Region Glioblastoma, a Case Report and Literature Review
by: Hayley Beacher Stowe, et al.
Published: (2017-06-01)

Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma
by: Simin Hemati, et al.
Published: (2014-01-01)

FM19G11 inhibits O6‐methylguanine DNA‐methyltransferase expression under both hypoxic and normoxic conditions
by: Chao‐guo You, et al.
Published: (2018-07-01)

Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II–IV Glioma Recurrence
by: Ma L, et al.
Published: (2020-09-01)

CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
by: Luyan Mu, et al.
Published: (2017-11-01)

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase
by: Peter Y. M. Woo, et al.
Published: (2019-01-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
by: Mesti Tanja, et al.
Published: (2015-03-01)

Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation
by: Yufu Zhu, et al.
Published: (2021-07-01)

Concurrent Hypofractionated Three-dimensional Re-irradiation and Temozolomide in Recurrent Malignant Glioma
by: Doaa Ali Sharaf Eldeen, et al.
Published: (2012-04-01)

A Radiomics Model for Predicting Early Recurrence in Grade II Gliomas Based on Preoperative Multiparametric Magnetic Resonance Imaging
by: Zhen-hua Wang, et al.
Published: (2021-09-01)

LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients
by: Jin Zhang, et al.
Published: (2018-09-01)

Glioma recurrence following surgery: peritumoral or perilesional?
by: boudewijn evan der sanden, et al.
Published: (2016-03-01)

ATF5-Expression und MGMT-Promotormethylierungsänderungen in glialen Tumoren
by: Feldheim, Jonas Alexander
Published: (2021)